139 related articles for article (PubMed ID: 38152323)
1. Effect of viral eradication with direct-acting antiviral agents on iron parameters in patients with chronic hepatitis c and hyperferritinemia.
Castiella A; José Sánchez-Iturri M; Urreta I; Torrente S; Alcorta A; Zapata E
Can Liver J; 2023 Dec; 6(4):412-416. PubMed ID: 38152323
[TBL] [Abstract][Full Text] [Related]
2. Viral eradication restores normal iron status in chronic hepatitis C patients with abnormal iron studies.
Hasan Y; Brown K
Ann Hepatol; 2020; 19(4):422-426. PubMed ID: 32278667
[TBL] [Abstract][Full Text] [Related]
3. Effect of Direct Acting Antivirals (DAAs) on Myeloid-Derived Suppressor Cells Population in Egyptian Chronic Hepatitis C Virus Patients: A Potential Immunomodulatory Role of DAAs.
Abdulsamad B; Afifi M; Awaad AK; Elbendary W; Mustafa H; Elsherbini B
Viral Immunol; 2023 May; 36(4):259-267. PubMed ID: 36802279
[TBL] [Abstract][Full Text] [Related]
4. Direct-acting antivirals for chronic hepatitis C.
Jakobsen JC; Nielsen EE; Feinberg J; Katakam KK; Fobian K; Hauser G; Poropat G; Djurisic S; Weiss KH; Bjelakovic M; Bjelakovic G; Klingenberg SL; Liu JP; Nikolova D; Koretz RL; Gluud C
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD012143. PubMed ID: 28922704
[TBL] [Abstract][Full Text] [Related]
5. Gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced magnetic resonance imaging for evaluating fibrosis regression in chronic hepatitis C patients after direct-acting antiviral.
Li XH; Huang R; Yang M; Wang J; Gao YH; Jin Q; Ma DL; Wei L; Rao HY
World J Gastroenterol; 2022 May; 28(20):2214-2226. PubMed ID: 35721884
[TBL] [Abstract][Full Text] [Related]
6. Regression in hepatic fibrosis in elderly Chinese patients with hepatitis C receiving direct-acting antiviral treatment.
Niu B; Zang W; Zhou H; Mi Y; Lu C; Li P
BMC Gastroenterol; 2023 Apr; 23(1):102. PubMed ID: 37013471
[TBL] [Abstract][Full Text] [Related]
7. Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland.
Bachofner J; Valli PV; Bergamin I; Kröger A; Künzler P; Baserga A; Braun DL; Seifert B; Moncsek A; Fehr J; Semela D; Magenta L; Müllhaupt B; Terziroli Beretta-Piccoli B; Mertens J; The Swiss Hepatitis C Cohort Study
Swiss Med Wkly; 2018; 148():w14560. PubMed ID: 29376557
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and Outcome of Serum Autoantibodies in Chronic Hepatitis C Patients Undergoing Direct-Acting Antiviral Treatment.
Romano C; Tortorella O; Dalla Mora L; Di Stasio D; Sellitto A; Adinolfi LE; Marrone A
Front Immunol; 2022; 13():882064. PubMed ID: 35479086
[TBL] [Abstract][Full Text] [Related]
9. Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: A prospective four-years follow-up study.
Ji D; Chen GF; Niu XX; Zhang M; Wang C; Shao Q; Wu V; Wang Y; Cheng G; Hurwitz SJ; Schinazi RF; Lau G
Metabol Open; 2021 Jun; 10():100090. PubMed ID: 33889834
[TBL] [Abstract][Full Text] [Related]
10. Lipids, glucose and iron metabolic alterations in chronic hepatitis C after viral eradication - comparison of the new direct-acting antiviral agents with the old regimens.
Carvalho JR; Velosa J; Serejo F
Scand J Gastroenterol; 2018; 53(7):857-863. PubMed ID: 29779403
[TBL] [Abstract][Full Text] [Related]
11. Sofosbuvir and Velpatasvir Regimen Outcome for Chronic Hepatitis C Patients With End-Stage Renal Disease Undergoing Hemodialysis.
Shahid S; Asghar S; Mahmood T; Fatima M; Rasheed A; Asghar S
Cureus; 2023 Sep; 15(9):e45680. PubMed ID: 37868481
[TBL] [Abstract][Full Text] [Related]
12. Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP).
Cespiati A; Petta S; Lombardi R; Di Marco V; Calvaruso V; Bertelli C; Pisano G; Fatta E; Sigon G; Iuculano F; Crapanzano L; Gibilaro G; Francione P; Craxì A; Fargion S; Fracanzani AL
Dig Liver Dis; 2021 Oct; 53(10):1301-1307. PubMed ID: 33214063
[TBL] [Abstract][Full Text] [Related]
13. Distribution of chronic hepatitis C genotype and evaluation of clinical factors affecting direct-acting antiviral treatment responses in the Western Black Sea Region, Turkey.
Gok Sargin Z; Dusunceli I
Eur Rev Med Pharmacol Sci; 2022 Oct; 26(19):7256-7262. PubMed ID: 36263536
[TBL] [Abstract][Full Text] [Related]
14. [Serum iron parameters in chronic hepatitis C patients and comparison of the results before and during antiviral treatment].
Bolewska B; Wojtacha A; Juszczyk J; Przedwojewski M
Pol Merkur Lekarski; 2005 May; 18(107):552-5. PubMed ID: 16161954
[TBL] [Abstract][Full Text] [Related]
15. Decentralized care with generic direct-acting antivirals in the management of chronic hepatitis C in a public health care setting.
Dhiman RK; Grover GS; Premkumar M; Taneja S; Duseja A; Arora S; Rathi S; Satsangi S; Roy A;
J Hepatol; 2019 Dec; 71(6):1076-1085. PubMed ID: 31325468
[TBL] [Abstract][Full Text] [Related]
16. High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study.
Mancuso ME; Linari S; Santagostino E; Bartolozzi D; D'Ambrosio R; Borghi M; Lampertico P; Peyvandi F; Castaman G; Aghemo A
Liver Int; 2020 May; 40(5):1062-1068. PubMed ID: 31876354
[TBL] [Abstract][Full Text] [Related]
17. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
Cheng TS; Liang PC; Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Hsieh PH; Chuang WL; Yu ML
Kaohsiung J Med Sci; 2021 Apr; 37(4):334-345. PubMed ID: 33151016
[TBL] [Abstract][Full Text] [Related]
18. Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence.
Nuño Solinís R; Arratibel Ugarte P; Rojo A; Sanchez Gonzalez Y
Infect Dis Ther; 2016 Dec; 5(4):491-508. PubMed ID: 27783223
[TBL] [Abstract][Full Text] [Related]
19. IP-10 Interferes With the Antiviral Response of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection.
Wang Y; Hu Y; Zhang X; Luo Y; Ma L; Lu J; Liang Q; Xu C; Zhao C; Pan CQ
Front Public Health; 2022; 10():911551. PubMed ID: 35923969
[TBL] [Abstract][Full Text] [Related]
20. Direct-Acting Antivirals Improve Treatment Outcomes in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Nationwide, Multi-center, Retrospective Cohort Study.
Hyun HK; Cho EJ; Park SY; Hong YM; Kim SS; Kim HY; Heo NY; Park JG; Sinn DH; Kang W; Jeong SW; Song MJ; Park H; Lee D; Lee YS; Cho SB; An CS; Rhee HJ; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Lee JH; Yu SJ; Kim YJ; Yoon JH; Tak WY; Kweon YO; Yoon KT; Cho M; Cheong JY; Park SH; Kim SU;
Dig Dis Sci; 2021 Jul; 66(7):2427-2438. PubMed ID: 32856240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
